Scarica l'app Stockscreener
3.09
3.44%
-0.11
Dopo l'orario di chiusura:
2.66
-0.43
-13.92%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.20
Aprire:
$2.86
Volume 24 ore:
289.86K
Relative Volume:
0.82
Capitalizzazione di mercato:
$6.90M
Reddito:
-
Utile/perdita netta:
$-9.64M
Rapporto P/E:
-6.7174
EPS:
-0.46
Flusso di cassa netto:
$-10.11M
1 W Prestazione:
+60.94%
1M Prestazione:
+1.48%
6M Prestazione:
+1.81%
1 anno Prestazione:
-59.45%
Intervallo 1D:
$2.82
$3.20
Intervallo di 1 settimana:
$1.72
$4.10
Portata 52W:
$1.72
$10.66
Gt Biopharma Inc Stock (GTBP) Company Profile
Nome
Gt Biopharma Inc
Settore
Industria
Telefono
(800) 304-9888
Indirizzo
315 MONTGOMERY STREET, SAN FRANCISCO
Confronta GTBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.84 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1446 | 305.16M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.879 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.23 | 139.09M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.07 | 52.94M | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | ROTH MKM | Buy |
| 2021-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | B. Riley Securities | Buy |
| 2021-03-17 | Iniziato | ROTH Capital | Buy |
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
GT Biopharma files automatic mixed securities shelf - MSN
Stock market today: Traws Pharma +231.47%, Rumble +59.02% among top gainers in early trading - Business Upturn
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart
GTBP Stock Hits 52-Week Low at $1.92 Amid Market Challenges - Investing.com
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
New Data Supports BLA Package - Streetwise Reports
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
BeautyHealth Releases 2024 Skintuition Report - Quantisnow
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Nanobodies Market Is Booming Worldwide 2024-2031 | Merck KGaA, - openPR
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
FDA Decision on Drug for Bone Marrow Due Early 2025 - Streetwise Reports
United States Nanobodies Market Size, Trends, Growth, - openPR
Roth Capital Weighs in on GT Biopharma FY2024 Earnings - Defense World
Brokers Set Expectations for GT Biopharma Q4 Earnings - Defense World
Roth Capital Upgrades GT Biopharma (NASDAQ:GTBP) to “Strong-Buy” - Defense World
Is This California Biopharma Co. In the Right Place at the Right Time? - Streetwise Reports
Approval Sought in Japan for New Drug to Lower Cholesterol - Streetwise Reports
Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative - Streetwise Reports
GT Biopharma (NASDAQ:GTBP) Now Covered by Analysts at Roth Mkm - Defense World
Roth/MKM bullish on GT Biopharma stock, sees upside from GTB-3650 revenue potential - Investing.com
Nanobodies Market Future Business Opportunities 2024-2031 | - openPR
GT Biopharma faces Nasdaq delisting over equity shortfall - Investing.com
GT Biopharma faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GT Biopharma (NASDAQ:GTBP) Enters Investigator Initiated Clinical Trial Agreement with the University of Minnesota - Defense World
GT Biopharma inks clinical trial agreement for cancer treatment - Investing.com
GT Biopharma inks clinical trial agreement for cancer treatment By Investing.com - Investing.com UK
GT Metabolic™ Solutions, Inc., announces completion of the first magnetic compression anastomosis cases in the USA following FDA clearance of its linear magnet technologythe MagDI™ System - Yahoo Finance
GT Biopharma Inc. (GTBP) Quarterly 10-Q Report - Quartzy
GT Biopharma Reports Third Quarter 2024 Financial Results - The Manila Times
GT Biopharma Reports $3.4M Q3 Loss, Advances Key Clinical Trial Timeline | GTBP Stock News - StockTitan
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Hydrafacial Announces Glow Getter Scholarship Program in Support of Estheticians - Quantisnow
Nanobodies Market Forecast CAGR 24.1% Projected for Size, Growth, and Share 2024-2031 | Proteintech Group, - EIN News
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
Gt Biopharma Inc Azioni (GTBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.50%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):